$266 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 67 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 56.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LBIO | Sell | LION BIOTECHNOLOGIES INC | $26,582,000 | +1.5% | 3,229,916 | -0.1% | 9.98% | -20.7% |
| VCYT | Sell | VERACYTE INC | $23,931,000 | +49.3% | 3,144,649 | -1.3% | 8.98% | +16.6% |
| IMMU | Sell | IMMUNOMEDICS INC | $12,513,000 | +28.4% | 3,850,000 | -8.3% | 4.70% | +0.3% |
| Sell | NEURODERM LTD | $8,560,000 | -16.9% | 462,956 | -27.0% | 3.21% | -35.1% | |
| ASND | Sell | ASCENDIS PHARMA A Ssponsored adr | $7,296,000 | +16.3% | 363,000 | -23.2% | 2.74% | -9.2% |
| OXFD | Sell | OXFORD IMMUNOTEC GLOBAL PLC | $5,122,000 | +36.4% | 407,815 | -2.3% | 1.92% | +6.5% |
| IWM | Sell | ISHARES TRput | $4,968,000 | -13.6% | 40,000 | -20.0% | 1.86% | -32.5% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $4,958,000 | -21.8% | 670,000 | -42.3% | 1.86% | -38.9% |
| DERM | Sell | DERMIRA INC | $3,619,000 | -27.2% | 107,000 | -37.1% | 1.36% | -43.1% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $3,071,000 | +23.9% | 50,000 | -61.5% | 1.15% | -3.2% |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $2,776,000 | -44.2% | 30,000 | -53.1% | 1.04% | -56.5% |
| PGNX | Sell | PROGENICS PHARMACEUTICALS IN | $2,737,000 | +44.5% | 432,370 | -3.7% | 1.03% | +13.0% |
| SRPT | Sell | SAREPTA THERAPEUTICS INCcall | $2,438,000 | +59.8% | 39,700 | -50.4% | 0.92% | +24.8% |
| TSRO | Sell | TESARO INC | $2,275,000 | -9.8% | 22,700 | -24.3% | 0.85% | -29.5% |
| ATRC | Sell | ATRICURE INC | $1,047,000 | -34.4% | 66,186 | -41.4% | 0.39% | -48.8% |
| AKTX | Sell | AKARI THERAPEUTICS PLCsponsored adr | $197,000 | -55.8% | 23,169 | -30.0% | 0.07% | -65.4% |
| RLYP | Exit | RELYPSA INCcall | $0 | – | -10,000 | -100.0% | -0.09% | – |
| AUDC | Exit | AUDIOCODES LTDord | $0 | – | -45,035 | -100.0% | -0.09% | – |
| CYTR | Exit | CYTRX CORPput | $0 | – | -100,000 | -100.0% | -0.11% | – |
| CDNA | Exit | CAREDX INC | $0 | – | -64,627 | -100.0% | -0.13% | – |
| BEAT | Exit | BIOTELEMETRY INC | $0 | – | -34,630 | -100.0% | -0.27% | – |
| IRWD | Exit | IRONWOOD PHARMACEUTICALS INC | $0 | – | -50,000 | -100.0% | -0.31% | – |
| RPTP | Exit | RAPTOR PHARMACEUTICAL CORP | $0 | – | -174,708 | -100.0% | -0.45% | – |
| OLED | Exit | UNIVERSAL DISPLAY CORP | $0 | – | -15,000 | -100.0% | -0.49% | – |
| RXDX | Exit | IGNYTA INC | $0 | – | -229,748 | -100.0% | -0.60% | – |
| SGY | Exit | STONE ENERGY CORPput | $0 | – | -108,100 | -100.0% | -0.63% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -140,969 | -100.0% | -0.64% | – |
| RIGL | Exit | RIGEL PHARMACEUTICALS INC | $0 | – | -747,748 | -100.0% | -0.80% | – |
| RTRX | Exit | RETROPHIN INC | $0 | – | -98,788 | -100.0% | -0.84% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -42,000 | -100.0% | -0.92% | – |
| CYNA | Exit | CYNAPSUS THERAPEUTICS INC | $0 | – | -115,400 | -100.0% | -0.93% | – |
| AGN | Exit | ALLERGAN PLC | $0 | – | -8,500 | -100.0% | -0.94% | – |
| PACB | Exit | PACIFIC BIOSCIENCES CALIF IN | $0 | – | -300,000 | -100.0% | -1.01% | – |
| INSM | Exit | INSMED INC | $0 | – | -220,000 | -100.0% | -1.04% | – |
| PODD | Exit | INSULET CORP | $0 | – | -75,000 | -100.0% | -1.09% | – |
| MDVN | Exit | MEDIVATION INC | $0 | – | -50,000 | -100.0% | -1.45% | – |
| RRM | Exit | RR MEDIA LTD | $0 | – | -611,818 | -100.0% | -3.84% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.